2. Search Result
Search Result
Results for "

neovascularization

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

3

Biochemical Assay Reagents

13

Peptides

4

Inhibitory Antibodies

5

Natural
Products

1

Click Chemistry

10

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0988
    Deferoxamine mesylate
    Maximum Cited Publications
    397 Publications Verification

    Desferrioxamine B mesylate; DFOM

    		 Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine mesylate
  • HY-B1625
    Deferoxamine
    Maximum Cited Publications
    397 Publications Verification

    Deferoxamine B; Deferriferrioxamine B; Deferrioxamine

    		 HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine
  • HY-N2464
    Maltotetraose
    1 Publications Verification

    Amylotetraose; Fujioligo 450; α-1,4-Tetraglucose

    		 TNF Receptor Endogenous Metabolite Bacterial Integrin NF-κB Cardiovascular Disease Inflammation/Immunology
    Maltotetraose can serve as a substrate for enzyme-linked assays to measure amylase activity in biological fluids. Maltotetraose has oral active, and reduces TNF-α-induced inflammatory responses by inhibiting NF-κB activity and decreasing ICAM-1 expression. Maltotetraose also inhibits PDGF-induced vascular smooth muscle cell migration and neovascularization. Additionally, Maltotetraose derivatives can function as probes for detecting bacterial infections by targeting the maltodextrin transporter. With good long-term safety, Maltotetraose holds promise for research in atherosclerosis-related diseases .
    Maltotetraose
  • HY-166648
    DSPE-PEG2000-Maleimide sodium (purity>99%)
    1 Publications Verification

    		 Liposome Cancer
    DSPE-PEG2000-Maleimide sodium (purity>99%) is a functional lipid component and a thiol-reactive crosslinker. DSPE-PEG2000-Maleimide sodium (purity>99%) undergoes Michael addition with the thiol groups of thiolated or cyclic RGD peptides to form stable thioether bonds and DSPE-PEG2000-RGD. DSPE-PEG2000-Maleimide sodium (purity>99%) is applicable to research on drug delivery .
    DSPE-PEG2000-Maleimide sodium (purity>99%)
  • HY-P2333
    LCKLSL
    5+ Cited Publications

    		 Annexin A Cardiovascular Disease
    LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles .
    LCKLSL
  • HY-N1419
    Vaccarin
    1 Publications Verification

    		 AMPK Akt ERK p38 MAPK NF-κB Nuclear Factor of activated T Cells (NFAT) JNK Cardiovascular Disease Metabolic Disease
    Vaccarin is an orally active flavonoid glycoside with multiple biological functions. Vaccarin promotes neovascularization by activating AKT and ERK. Vaccarin activates the AMPK signaling pathway to improve insulin resistance and steatosis. Vaccarin is a MAPK, NF-κB, and NFAT inhibitor, effectively blocking RANKL-induced osteoclastogenesis .
    Vaccarin
  • HY-118530
    Bucillamine
    2 Publications Verification

    SA96; Thiobutarit

    		 VEGFR Cardiovascular Disease Inflammation/Immunology
    Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .
    Bucillamine
  • HY-P2333A
    LCKLSL hydrochloride
    5+ Cited Publications

    		 Annexin A Cardiovascular Disease
    LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL hydrochloride also inhibits the generation of plasmin and has anti-angiogenic roles .
    LCKLSL hydrochloride
  • HY-108544
    INCA-6
    4 Publications Verification

    Triptycene-1,4-quinone

    		 Nuclear Factor of activated T Cells (NFAT) Cardiovascular Disease
    INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 specifically blocks targeting of NFAT(P) substrate to the calcineurin (CN) phosphatase site and is an effective inhibitor of CN-NFAT signaling .
    INCA-6
  • HY-B0988R
    Deferoxamine mesylate (Standard)

    Desferrioxamine B mesylate (Standard); DFOM (Standard)

    		 Reference Standards Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (mesylate) (Standard) is the analytical standard of Deferoxamine (mesylate). This product is intended for research and analytical applications. Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine mesylate (Standard)
  • HY-P3226
    JB-1

    		IGF-1R VEGFR Drug Derivative Cardiovascular Disease Neurological Disease
    JB-1, an IGF-I analog, is a selective IGF-I receptor inhibitor that does not interact with IGF-II. JB-1 competes with IGF-I for binding to IGF-1R and blocks receptor autophosphorylation. JB-1 increases the level of sVEGFR-1. JB-1 normalizes retinal abnormalities, including reducing retinal neovascularization. JB-1 is applicable to studies related to oxygen-induced retinopathy .
    JB-1
  • HY-P3369
    Gersizangitide

    AXT-107

    		 VEGFR Tie Akt Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of Tie2. Gersizangitide can block VEGF receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .
    Gersizangitide
  • HY-118672
    HNHA

    		HDAC MMP HIF/HIF Prolyl-Hydroxylase Cancer
    HNHA is a potent HDAC inhibitor with an IC50 of 100 nM. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer .
    HNHA
  • HY-N7271
    Solanidine
    1 Publications Verification

    		 RAD51 MDM-2/p53 Cardiovascular Disease Cancer
    Solanidine is an orally active cholestane alkaloid. Solanidine can be isolated from potato. Solanidine decreases RAD51 and increases γH2AX and p53. Solanidine has anti-tumor effects on LLC tumors and lung cancer. Solanidine promotes breast cancer cell proliferation. Solanidine reduces neovascularization. Solanidine causes abortion in some pregnant mice .
    Solanidine
  • HY-126195
    Fluoflavine

    ML-090

    		 NADPH Oxidase Neurological Disease
    Fluoflavine (ML-090) is a selective NOX1 inhibitor and reactive oxygen species inhibitor. Fluoflavine reduces reactive oxygen species production, NOX1-mediated downstream signaling events, and oxygen-glucose deprivation-induced retinal ganglion cell death. Fluoflavine inhibits NADPH oxidase activity and pathological retinal neovascularization induced by oxygen-induced retinopathy in the retinas of ischemic mice. Fluoflavine can be used in studies related to retinal ischemia-reperfusion injury and proliferative retinopathy .
    Fluoflavine
  • HY-117133
    Nesvategrast

    SF0166

    		 Integrin Metabolic Disease
    Nesvategrast (SF0166) is a potent and selective αvβ3 antagonist with IC50 values of 0.6 nM, 8 nM, and 13 nM for αvβ3, αvβ6, and αvβ8, respectively. Nesvategrast inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 values of 7.6 pM to 76 nM. Nesvategrast decreases neovascularization in the oxygen-induced retinopathy mouse model .
    Nesvategrast
  • HY-P99830
    Conbercept

    KH902

    		 VEGFR TNF Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology Cancer
    Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC50 = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (Kd = 0.5 pM), VEGF-B (Kd = 8 pM), VEGF-C, and PlGF (Kd = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .
    Conbercept
  • HY-166648A
    DSPE-PEG-Maleimide ammonium (MW 2000)
    1 Publications Verification

    		 Liposome Others
    DSPE-PEG-Maleimide ammonium (MW 2000) is a functional lipid component and a thiol-reactive crosslinker. DSPE-PEG-Maleimide ammonium (MW 2000) undergoes Michael addition with the thiol groups of thiolated or cyclic RGD peptides to form stable thioether bonds and DSPE-PEG (2000)-RGD. DSPE-PEG-Maleimide ammonium (MW 2000) is applicable to research on drug delivery .
    DSPE-PEG-Maleimide ammonium (MW 2000)
  • HY-P4253
    Arginyl-Glutamine

    H-Arg-Gln-OH

    		 VEGFR Cardiovascular Disease
    Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy .
    Arginyl-Glutamine
  • HY-153484A
    Bevasiranib sodium

    		VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib sodium
  • HY-125639
    (rac)-AR-13503

    (rac)-AR-13324 M1 metabolite

    		 PKC ROCK Cardiovascular Disease
    (rac)-AR-13503 ((rac)-AR-13324 M1 metabolite) is the isoform of AR-13503 (HY-12798C). AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice .
    (rac)-AR-13503
  • HY-172423
    Darlifarnib

    KO-2806

    		 Farnesyl Transferase mTOR VEGFR Cancer
    Darlifarnib (KO-2806) is an orally active farnesyl transferase inhibitor. Darlifarnib inhibits the mTORC1 signaling pathway, thereby enhancing the anti-angiogenic properties of tyrosine kinase inhibitors. When used in combination with anti-VEGFR tyrosine kinase inhibitors, Darlifarnib promotes renal cell carcinoma tumor regression and inhibits tumor neovascularization. Darlifarnib sensitizes renal cell carcinoma tumors that progress after anti-VEGFR TKI treatment .
    Darlifarnib
  • HY-W1048555A
    Mal-PEG2000-SCM

    		Biochemical Assay Reagents Others
    Mal-PEG2000-SCM is a heterobifunctional PEG crosslinker bearing maleimide and succinimidyl carboxymethyl ester functional groups. MMal-PEG2000-SCM conjugates the F3 peptide to nanoparticles: the SCM group reacts with amino groups on the nanoparticle surface to form amide groups, while the MAL group reacts with thiol groups of the F3 peptide to form carbon-sulfur bonds. Mal-PEG-SCM enables unidirectional addition of linkers, ensuring that appropriate functional groups are available for RGD incorporation. Mal-PEG2000-SCM can be used in the development of nanoparticles targeting specific tumor cells .
    Mal-PEG2000-SCM
  • HY-116868
    Anecortave acetate

    Anecortave

    		 PAI-1 Cardiovascular Disease
    Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases .
    Anecortave acetate
  • HY-15492
    AG-13958
    1 Publications Verification

    AG-013958

    		 VEGFR Cardiovascular Disease
    AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
    AG-13958
  • HY-132126
    SPHINX

    		SRPK Others
    SPHINX is a selective SRPK1 inhibitor with an IC50 value of 0.58 μM. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degenaration) AMD .
    SPHINX
  • HY-116312
    8-pCPT-2′-O-Me-cAMP

    8-CPT-2'-O-Me-cAMP

    		 Ras Cardiovascular Disease
    8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP), an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50 >10 μM). 8-pCPT-2′-O-Me-cAMP stimulates Epac-mediated Ca 2+ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .
    8-pCPT-2′-O-Me-cAMP
  • HY-B1625R
    Deferoxamine (Standard)
    3 Publications Verification

    Deferoxamine B (Standard); Deferriferrioxamine B (Standard); Deferrioxamine (Standard)

    		 Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Deferoxamine (Standard) is the analytical standard of Deferoxamine. This product is intended for research and analytical applications. Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
    Deferoxamine (Standard)
  • HY-P4253A
    Arginyl-Glutamine TFA

    H-Arg-Gln-OH TFA

    		 VEGFR Cardiovascular Disease
    Arginyl-Glutamine TFA is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy .
    Arginyl-Glutamine TFA
  • HY-N16552
    Embinin

    		Apoptosis Cardiovascular Disease
    Embinin is a natural product that can be isolated from Petals of Iris germanica Linnaeous. Embinin can enhance lumbar disc neovascularization and induces apoptosis of nucleus pulposus cells in lumbar disc herniation rats .
    Embinin
  • HY-101990
    IMS2186

    		VEGFR Others
    IMS2186 is an anti-choroidal neovascularization (CNV) agent that inhibits angiogenesis upstream of VEGF. IMS2186 can arrest cancer cell cycle in G2/M phase, thus exerting anti-proliferation and anti-angiogenesis effects. IMS2186 has no intraocular toxicity and reduces the amount of eye leakage and diseased cells .
    IMS2186
  • HY-145604
    Vicasinabin

    RG7774

    		 Cannabinoid Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC50 values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R. Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization .
    Vicasinabin
  • HY-158821A
    ISTH0036 sodium

    		TGF-beta/Smad Neurological Disease
    ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases .
    ISTH0036 sodium
  • HY-116030
    JNJ-26076713

    		Integrin Metabolic Disease
    JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization .
    JNJ-26076713
  • HY-136340
    21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione

    		Glucocorticoid Receptor NF-κB Metabolic Disease Inflammation/Immunology
    21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is an intermediate of delta 9,11 steroids synthesis, for example, Vamorolone (HY-109017). The delta 9,11 steroids are modifications of glucocorticoids and has anti-inflammatory properties. The delta 9,11 steroids are agents for protection against cell damage (lipid peroxidation) and inhibition of neovascularization .
    21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione
  • HY-158821
    ISTH0036

    		TGF-beta/Smad Neurological Disease
    ISTH0036 is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases .
    ISTH0036
  • HY-153484
    Bevasiranib

    		VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib
  • HY-179473
    MK-0626

    		Dipeptidyl Peptidase NO Synthase Cardiovascular Disease Metabolic Disease
    MK-0626 is a selective, orally active DPP-4 inhibitor with an IC50 of 6.3 nM. MK-0626 increases endothelial nitric oxide synthetase expression. MK-0626 improves neovascularization, attenuates hepatic steatosis, attenuates pancreatic islet injury. MK-0626 can be used in the research of diabetes and non-alcoholic fatty liver disease .
    MK-0626
  • HY-P10783
    BGC0222

    		Peptide-Drug Conjugates (PDCs) Integrin Cancer
    BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors .
    BGC0222
  • HY-118530R
    Bucillamine (Standard)

    SA96 (Standard); Thiobutarit (Standard)

    		 Reference Standards VEGFR Cardiovascular Disease Inflammation/Immunology
    Bucillamine (Standard) is the analytical standard of Bucillamine. This product is intended for research and analytical applications. Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) .
    Bucillamine (Standard)
  • HY-P10797
    TAT-N24

    		NF-κB HIF/HIF Prolyl-Hydroxylase VEGFR TNF Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology
    TAT-N24 is a cell-permeable TAT peptide as a p55PIK signaling inhibitor. TAT-N24 is effective for corneal neovascularization (CNV) and ocular inflammation by inhibiting the HIF-1α/NF-κB signaling pathway in corneal suture (CS). TAT-N24 also inhibits corneal neovascularization .
    TAT-N24
  • HY-P10335
    SPARC (119-122) (mouse)

    		Biochemical Assay Reagents Metabolic Disease
    SPARC (119-122) (mouse) stimulates endothelial cell proliferation and angiogenesis. SPARC (119-122) (mouse) can be used to enhance neovascularization in modified polypropropylene biomaterials .
    SPARC (119-122) (mouse)
  • HY-152087
    DCZ19931

    		ERK p38 MAPK Cardiovascular Disease
    DCZ19931 is a potent multi-targeting kinase inhibitor. DCZ19931 has anti-angiogenic effects on ocular neovascularization. DCZ19931 also inhibits ERK1/2-MAPK and p38-MAPK signaling .
    DCZ19931
  • HY-172334
    2N12B

    		Liposome Metabolic Disease
    2N12B is a bioreducible ionizable lipid containing disulfide bonds. 2N12B can be used to prepare lipid nanoparticles (LNPs) for the delivery of mRNA in vitro and in vivo. Lipid nanoparticles containing 2N12B can deliver siRNA to inhibit retinal neovascularization .
    2N12B
  • HY-N7271R
    Solanidine (Standard)

    		Reference Standards RAD51 MDM-2/p53 Cardiovascular Disease Cancer
    Solanidine (Standard) is the analytical standard of Solanidine. This product is intended for research and analytical applications. Solanidine is an orally active cholestane alkaloid. Solanidine can be isolated from potato. Solanidine decreases RAD51 and increases γH2AX and p53. Solanidine has anti-tumor effects on LLC tumors and lung cancer. Solanidine promotes breast cancer cell proliferation. Solanidine reduces neovascularization. Solanidine causes abortion in some pregnant mice .
    Solanidine (Standard)
  • HY-P991310
    Lpathomab

    LT3015; LT-3000

    		 LPL Receptor Neurological Disease Cancer
    Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Lpathomab
  • HY-125542
    DCZ3301

    		Apoptosis JAK STAT ERK PI3K Akt Cancer
    DCZ3301 is an apoptosis inducer. DCZ3301 modulates JAK2/STAT3, ERK1/2, and PI3K/AKT pathways. DCZ3301 induces G2/M and M phase cell cycle arrest and inhibits cell proliferation and viability. DCZ3301 enhances DNA damage, inhibits DNA repair, and suppresses angiogenesis. DCZ3301 can be used for the research of diffuse large B-cell lymphoma, multiple myeloma and leukemia/lymphoma .
    DCZ3301
  • HY-131384
    8,11,14-Eicosatriynoic acid

    8,11,14-Icosatriynoic acid

    		 COX Others
    8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    8,11,14-Eicosatriynoic acid
  • HY-182372
    SH-11037

    		Epoxide Hydrolase Neurological Disease
    SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization .
    SH-11037
  • HY-P11775A
    Peptide HRH acetate

    		VEGFR Cardiovascular Disease
    Peptide HRH acetate is a polypeptide that specifically binds to VEGF receptors. Peptide HRH acetate inhibits VEGF-stimulated endothelial cell proliferation. Peptide HRH acetate inhibits angiogenesis and suppresses corneal neovascularization. Peptide HRH acetate can be used in anti-angiogenesis related studies .
    Peptide HRH acetate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: